Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

BioAlliance Pharma Expands and Strengthens Its Industrial Property Assets

Published: Friday, July 12, 2013
Last Updated: Friday, July 12, 2013
Bookmark and Share
BioAlliance Pharma SA was granted two patents by the American and Japanese Offices protecting two of its products; Oravig® (miconazole) and Sitavig® (acyclovir).

With these two new patents, BioAlliance Pharma’s patent portfolio consists of 19 families of published patents, including 285 patents and patent applications for technologies or innovative products. More than 70 % of the portfolio is composed of patents providing long-term protection for the products.

“The industrial property is a key asset for BioAlliance and lies at the core of the Company’s growth strategy. The reinforcement and the territory expansion of our patents allow to ensure the largest and longest possible protection, optimizing our programs’ value. One such example is the grant of these two new patents”, declared Judith Greciet, CEO of BioAlliance Pharma.

New protection of Sitavig® in Japan

In addition to the first Japanese patent protecting the mucoadhesive tablet, and further to the patent protections obtained for Europe, the US and China, this grant is the first one specific to Sitavig® in Japan for the treatment of labial herpes.

New protection of Oravig® in the US

The American patent office announced its decision to deliver a new grant covering Oravig®, a miconazole mucoadhesive tablet for the treatment of oropharyngeal candidiasis. This new patent enables BioAlliance to expand the scope of protection already given by two US patents protecting Oravig® until 2022.

“These two patent grants strengthen and extend the protection for both Oravig® and Sitavig® in the US and Japan respectively while stressing out the innovative nature of the Lauriad® mucoadhesive tablet formulation. Oravig®’s patent reinforces and ensures its protection for about ten more years on the US territory while coinciding with the commercial product launch initiated by Vestiq”, stated Aude Michel, Head of Corporate Business Development of BioAlliance Pharma. “The protection obtained for Sitavig® until 2027 on the Japanese territory should reinforce its attractiveness in our search for commercial partners on an international level”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioAlliance Pharma Announces Shareholders’ Meeting and Appointment of Independant Board Members
As a result of the shareholder’s meeting, Dr Russell Greig and Danièle Guyot-Caparros have been appointed as independent Board Members.
Monday, July 01, 2013
BioAlliance Pharma to Continue its Phase III Clinical Trial with Livatag®
The Data and Safety Monitoring Board (DSMB) has again recommended continuing the ReLive Phase III trial without modification.
Tuesday, May 14, 2013
BioAlliance Pharma’s Sitavig® Receives Market Authorization in the US
Authorization from the U.S. FDA for Sitavig® in the treatment of recurring Herpes labialis, marking the successful conclusion to the assessment procedure carried out by the American authorities.
Tuesday, April 16, 2013
BioAlliance Announces Phase I Trial for Fentanyl Lauriad® and the Submission of a Clonidine Lauriad® Phase II Clinical Trial Application
This clinical trial will evaluate the plasma pharmacokinetic parameters of Fentanyl Lauriad® in healthy volunteers.
Tuesday, October 13, 2009
BioAlliance Announces Positive Preliminary Pivotal Phase III Results in Herpes Labialis with Acyclovir Lauriad®
Study compared the efficacy and safety of a single dose acyclovir Lauriad® 50mg MBT versus matching placebo in recurrent oro-facial herpes.
Thursday, August 27, 2009
BioAlliance Pharma Submits Clinical Trial New Drug Application
Company announces submission of a Fentanyl Lauriad® clinical trial application to the French Drug Agency and approval by the Ethics Committee.
Wednesday, July 29, 2009
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos